OBJECTIVES: Persistent anal high-risk human papillomavirus (HR-HPV) infection is a major risk factor for anal cancer among MSM and transgender women (TGW). We aimed to estimate incidence, clearance, and persistence of anal HR-HPV in HIV-positive and HIV-negative MSM and TGW, and to assess factors for HR-HPV persistence. DESIGN: Prospective cohort study. METHODS: MSM and TGW aged at least 18 years, were enrolled from Indonesia, Malaysia, and Thailand, then followed up 6-monthly for 12 months. Anal swabs were collected at every visit for HR-HPV genotypes to define anal HR-HPV incidence, clearance, and persistence. Logistic regression was used to evaluate factors associated with HR-HPV persistence. RESULTS: Three hundred and twenty-five MSM and TGW were included in this study, of whom 72.3% were HIV-positive. The incidence of anal HR-HPV persistence was higher in HIV-positive than HIV-negative MSM participants (28.4/1000 vs. 13.9/1000 person-months). HIV-positive participants had HR-HPV lower clearance rate than HIV-negative participants (OR 0.3; 95% CI 0.1-0.7). The overall persistence of HR-HPV was 39.9% in HIV-positive and 22.8% HIV-negative participants. HPV-16 was the most persistent HR-HPV in both HIV-positive and HIV-negative participants. HIV infection (aOR 2.87; 95% CI 1.47-5.61), living in Kuala Lumpur (aOR 4.99; 95% CI 2.22-11.19) and Bali (aOR 3.39; 95% CI 1.07-10.75), being employed/freelance (aOR 3.99; 95% CI 1.48-10.77), and not being circumcised (aOR 2.29; 95% CI 1.07-4.88) were independently associated with anal HR-HPV persistence. CONCLUSION: HIV-positive MSM and TGW had higher risk of persistent anal HR-HPV infection. Prevention program should be made available and prioritized for HIV-positive MSM and TGW where resources are limited.
OBJECTIVES: Persistent anal high-risk human papillomavirus (HR-HPV) infection is a major risk factor for anal cancer among MSM and transgender women (TGW). We aimed to estimate incidence, clearance, and persistence of anal HR-HPV in HIV-positive and HIV-negative MSM and TGW, and to assess factors for HR-HPV persistence. DESIGN: Prospective cohort study. METHODS: MSM and TGW aged at least 18 years, were enrolled from Indonesia, Malaysia, and Thailand, then followed up 6-monthly for 12 months. Anal swabs were collected at every visit for HR-HPV genotypes to define anal HR-HPV incidence, clearance, and persistence. Logistic regression was used to evaluate factors associated with HR-HPV persistence. RESULTS: Three hundred and twenty-five MSM and TGW were included in this study, of whom 72.3% were HIV-positive. The incidence of anal HR-HPV persistence was higher in HIV-positive than HIV-negative MSM participants (28.4/1000 vs. 13.9/1000 person-months). HIV-positive participants had HR-HPV lower clearance rate than HIV-negative participants (OR 0.3; 95% CI 0.1-0.7). The overall persistence of HR-HPV was 39.9% in HIV-positive and 22.8% HIV-negative participants. HPV-16 was the most persistent HR-HPV in both HIV-positive and HIV-negative participants. HIV infection (aOR 2.87; 95% CI 1.47-5.61), living in Kuala Lumpur (aOR 4.99; 95% CI 2.22-11.19) and Bali (aOR 3.39; 95% CI 1.07-10.75), being employed/freelance (aOR 3.99; 95% CI 1.48-10.77), and not being circumcised (aOR 2.29; 95% CI 1.07-4.88) were independently associated with anal HR-HPV persistence. CONCLUSION: HIV-positive MSM and TGW had higher risk of persistent anal HR-HPV infection. Prevention program should be made available and prioritized for HIV-positive MSM and TGW where resources are limited.
Authors: Pierre Van Damme; Chris J L M Meijer; Dorothee Kieninger; Anne Schuyleman; Stephane Thomas; Alain Luxembourg; Martine Baudin Journal: Vaccine Date: 2016-06-25 Impact factor: 3.641
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Mary K Grabowski; Ronald H Gray; David Serwadda; Godfrey Kigozi; Patti E Gravitt; Fred Nalugoda; Steven J Reynolds; Maria J Wawer; Stephen Watya; Thomas C Quinn; Aaron A R Tobian Journal: Sex Transm Infect Date: 2014-01-30 Impact factor: 3.519
Authors: Jason J Ong; Sandra Walker; Andrew Grulich; Jennifer Hoy; Tim R H Read; Catriona Bradshaw; Marcus Chen; Suzanne M Garland; Alyssa Cornall; Richard Hillman; David J Templeton; Jane Hocking; Beng Eu; B K Tee; Eric P F Chow; Christopher K Fairley Journal: Sex Transm Dis Date: 2019-04 Impact factor: 2.830
Authors: Alexandra de Pokomandy; Danielle Rouleau; George Ghattas; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Eduardo L Franco; François Coutlée Journal: J Infect Dis Date: 2009-04-01 Impact factor: 5.226
Authors: Janet R Daling; Margaret M Madeleine; Lisa Godefroy Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: I Ketut Agus Somia; Nipat Teeratakulpisarn; Wifanto S Jeo; Ilias A Yee; Tippawan Pankam; Siriporn Nonenoy; Deondara Trachuntong; Pravit Mingkwanrungrueng; Made Dewi D Sukmawati; Reshmie Ramautarsing; Hanny Nilasari; Nany Hairunisa; Iskandar Azwa; Evy Yunihastuti; Tuti P Merati; Praphan Phanuphak; Joel Palefsky; Nittaya Phanuphak Journal: Medicine (Baltimore) Date: 2018-03 Impact factor: 1.889
Authors: Rebecca G Nowak; Søren M Bentzen; Lisa M Schumaker; Nicholas P Ambulos; Nicaise Ndembi; Wuese Dauda; Andrew Mitchell; Trevor J Mathias; Trevor A Crowell; Stefan D Baral; William A Blattner; Manhattan E Charurat; Joel M Palefsky; Kevin J Cullen Journal: Sex Transm Dis Date: 2022-04-01 Impact factor: 2.830
Authors: Caleb LoSchiavo; Paul A D'Avanzo; Connor Emmert; Kristen D Krause; Danielle C Ompad; Farzana Kapadia; Perry N Halkitis Journal: Am J Mens Health Date: 2022 Jul-Aug